Sagimet Biosciences, Inc. Class A (SGMT) Price & Analysis

Compare

1,498 Followers

SGMT Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.73 - $11.41

Previous CloseN/A

Volume1.06M

Average Volume (3M)647.58K

Market Cap

$220.42M

Enterprise Value$120.07M

Total Cash (Recent Filing)$125.41M

Total Debt (Recent Filing)$152.00K

Price to Earnings (P/E)―

Beta3.46

Next Earnings

Nov 12, 2025

EPS Estimate

-0.43

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.32

Shares Outstanding31,001,108

10 Day Avg. Volume451,038

30 Day Avg. Volume647,584

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.54

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-1.85

Forecast

1Y Price Target

$32.71

Price Target Upside360.06% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering8

Bulls Say, Bears Say

Bulls Say

Efficacy In Clinical TrialsDenifanstat has demonstrated strong efficacy in both MASH patients with stage F2/F3 fibrosis and patients with moderate to severe acne in completed Phase 2b and Phase 3 studies, respectively.

Financial StabilitySagimet Biosciences has enough cash, $135 million, to support operations through the completion of Phase 1 trials, indicating financial stability.

Partnership And Market ExpansionGrowing partnership interest in the MASH program indicates potential for market expansion and collaborative opportunities.

Bears Say

Financial PerformanceThe company reported a net loss of $10.4 million in the second quarter, which may be a concern for investors.

Market CompetitionDenifanstat is positioned as a non-antibiotic alternative, but strategic negotiations and marketing are required to ensure it competes successfully as a high-tier treatment.

Sagimet Biosciences, Inc. Class A News

Sagimet Biosciences announces anticipated upcoming milestones

Sagimet plans to initiate a Phase 1 clinical trial to evaluate the PK and tolerability of a combination...

26d ago

SGMT

Sagimet Biosciences reports Q2 EPS (32c), consensus (50c)

“We are making strong progress advancing our differentiated therapeutics, which are in development for the treatment of MASH...

26d ago

SGMT

Sagimet Biosciences initiated with an Outperform at Wedbush

Wedbush initiated coverage of Sagimet Biosciences (SGMT) with an Outperform rating and $28 price target Published first on...

28d ago

SGMT

Promising Clinical Developments and Strategic Positioning Make Sagimet Biosciences a Buy

Thomas Smith, an analyst from Leerink Partners, reiterated the Buy rating on Sagimet Biosciences, Inc. Class A. The...

20d ago

SGMT

Promising Growth Potential of Sagimet Biosciences: Buy Rating Justified by Strategic Trials and Strong Financial Position

TD Cowen analyst Ritu Baral has maintained their bullish stance on SGMT stock, giving a Buy rating on...

20d ago

SGMT

Promising Potential of Sagimet Biosciences’ FASN Inhibitors Drives Buy Rating

Analyst Yun Zhong of Wedbush reiterated a Buy rating on Sagimet Biosciences, Inc. Class A, retaining the price...

24d ago

SGMT

Sagimet Biosciences: Promising Advancements in FASN Inhibitor Platform and Strategic Growth Initiatives Justify Buy Rating

Sagimet Biosciences, Inc. Class A, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst...

24d ago

SGMT

Sagimet Biosciences Reports Progress in Acne and MASH Trials

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has released its Q2 earnings. Here is a breakdown of...

24d ago

SGMT

Sagimet Biosciences Enters New Sales Agreement with Leerink

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has issued an update. Sagimet Biosciences Inc. announced on August...

25d ago

SGMT

Sagimet Biosciences, Inc. Class A: Promising Combination Therapy for MASH Drives Buy Rating

Analyst Edward Nash from Canaccord Genuity maintained a Buy rating on Sagimet Biosciences, Inc. Class A and keeping...

25d ago

SGMT

Sagimet Biosciences Reports Q2 Results and Clinical Progress

Sagimet Biosciences, Inc. Class A ( ($SGMT) ) has shared an announcement. On August 13, 2025, Sagimet Biosciences...

26d ago

SGMT

Eli Lilly downgraded, Lyft upgraded: Wall Street’s top analyst calls

The most talked about and market moving research calls around Wall Street are now in one place. Here...

1M ago

CAT

FUN

Promising Prospects for Sagimet Biosciences: Buy Rating Backed by Innovative FASN Inhibitor Platform and Clinical Advancements

Brandon Folkes, an analyst from H.C. Wainwright, has initiated a new Buy rating on Sagimet Biosciences, Inc. Class...

1M ago

SGMT

Sagimet Biosciences assumed with a Buy at H.C. Wainwright

H.C. Wainwright analyst Brandon Folkes assumed coverage of Sagimet Biosciences (SGMT) with a Buy rating and $29 price...

1M ago

SGMT

SGMT FAQ

What was Sagimet Biosciences, Inc. Class A’s price range in the past 12 months?

Sagimet Biosciences, Inc. Class A lowest stock price was $1.73 and its highest was $11.41 in the past 12 months.

What is Sagimet Biosciences, Inc. Class A’s market cap?

Sagimet Biosciences, Inc. Class A’s market cap is $220.42M.

When is Sagimet Biosciences, Inc. Class A’s upcoming earnings report date?

Sagimet Biosciences, Inc. Class A’s upcoming earnings report date is Nov 12, 2025 which is in 65 days.

How were Sagimet Biosciences, Inc. Class A’s earnings last quarter?

Sagimet Biosciences, Inc. Class A released its earnings results on Aug 13, 2025. The company reported -$0.32 earnings per share for the quarter, beating the consensus estimate of -$0.508 by $0.188.

Is Sagimet Biosciences, Inc. Class A overvalued?

According to Wall Street analysts Sagimet Biosciences, Inc. Class A’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Sagimet Biosciences, Inc. Class A pay dividends?

Sagimet Biosciences, Inc. Class A does not currently pay dividends.

What is Sagimet Biosciences, Inc. Class A’s EPS estimate?

Sagimet Biosciences, Inc. Class A’s EPS estimate is -0.43.

How many shares outstanding does Sagimet Biosciences, Inc. Class A have?

Sagimet Biosciences, Inc. Class A has 31,001,108 shares outstanding.

What happened to Sagimet Biosciences, Inc. Class A’s price movement after its last earnings report?

Sagimet Biosciences, Inc. Class A reported an EPS of -$0.32 in its last earnings report, beating expectations of -$0.508. Following the earnings report the stock price went up 0.314%.

Which hedge fund is a major shareholder of Sagimet Biosciences, Inc. Class A?

Currently, no hedge funds are holding shares in SGMT

Sagimet Biosciences, Inc. Class A Stock Smart Score

Outperform

Fundamentals

Return on Equity

-37.89%

Trailing 12-Months

Asset Growth

-27.31%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Sagimet Biosciences, Inc. Class A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional lipid metabolism pathways. Its lead drug candidate is Denifanstat, a FASN inhibitor for the treatment of nonalcoholic steatohepatitis and acne. The company is also developing TVB-3567, a FASN inhibitor for the treatment of various types of cancers. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

Sagimet Biosciences, Inc. Class A (SGMT) Earnings & Revenues

Historic Earnings Reports

SGMT Stock 12 Month Forecast

Average Price Target

$32.71

▲(360.06% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"1":"$1","68":"$68","17.75":"$17.75","34.5":"$34.5","51.25":"$51.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":67,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$67.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.71,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.71</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":25,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$25.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[1,17.75,34.5,51.25,68],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,12.76923076923077,17.28846153846154,21.807692307692307,26.326923076923077,30.846153846153847,35.36538461538461,39.88461538461539,44.40384615384615,48.92307692307692,53.44230769230769,57.96153846153846,62.480769230769226,{"y":67,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,10.131538461538462,12.013076923076923,13.894615384615385,15.776153846153846,17.657692307692308,19.53923076923077,21.42076923076923,23.302307692307693,25.183846153846154,27.065384615384616,28.946923076923078,30.82846153846154,{"y":32.71,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,8.25,9.538461538461538,10.826923076923077,12.115384615384617,13.403846153846153,14.692307692307693,15.980769230769232,17.26923076923077,18.557692307692307,19.846153846153847,21.134615384615387,22.423076923076923,23.711538461538463,{"y":25,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.16,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.48,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.12,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.33,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.36,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.5,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.4,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":2.58,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.93,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.49,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.03,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.25,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >